224
Participants
Start Date
December 6, 2010
Primary Completion Date
March 3, 2014
Study Completion Date
December 20, 2016
Axitinib (AG-013736)
Axitinib \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
Best Supportive Care
BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
Placebo
Placebo \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
Best Supportive Care
BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
National Taiwan University Hospital, Taipei
Chang Gung Medical Foundation Linkou Branch, Taoyuan District
Changhua Christian Hospital, Changhua
National Cheng Kung University Hospital, Tainan City
Chi-Mei Medical Center LiouYing, Tainan City
Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
Semmelweis Egyetem I.sz. Belgyógyászati Klinika, Budapest
CHC Clinique Saint-Joseph, Liège
Szegedi Tudományegyetem Onkoterápiás Klinika, Szeged
Universitair Ziekenhuis Gent, Ghent
UPCET-CIC Timone, Marseille
Medizinische Klinik mit Schwerpunkt, Berlin
CHU Cote de Nacre, Caen
Hospital of the University of Pennsylvania, Philadelphia
Penn Presbyterian Medical Center, Philadelphia
Unita Operativa Oncologia Medica IRCCS Fondazione Salvatore Maugeri, Pavia
CHRU de Purpan., Toulouse
Florida Hospital Transplant Center, Liver Unit, Orlando
Hopital Saint André, Bordeaux
Moffitt Cancer Center & Research Institute, Tampa
CHRU Montpellier-Hopital Saint Eloi - Departement Oncologie Medicale, Montpellier
Centre Eugène Marquis, Rennes
Istituto di Ematologia ed Oncologia Medica, Lorenzo ed Ariosto Seragnoli,, Bologna
"Policlinico S.Orsola-Malpighi Dipartimento di Ematologia e Scienze Oncologiche L. E A. Seragnoli", Bologna
Taichung Veterans General Hospital, Taichung
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori IRST, Meldola (FC)
University of Michigan, Ann Arbor
Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria aile Scotte, Siena
Universitätsklinikum Bonn, Bonn
Ospedale Versilia,Oncologia Medica, Lido Di Camaiore (LU)
Nebraska Methodist Hospital, Omaha
Hopital De La Croix-Rousse, Lyon
Hôpital Saint Antoine, Paris
Centre Hospitalier Universitaire d'Amiens, Amiens
Klinikum der Ludwig-Maximilians-Universitaet , Campus Grosshadern, München
Comprehensive Cancer Centers of Nevada, Las Vegas
Comprehensive Cancer Centers of Nevada, Las Vegas
UCSD Medical Center- La Jolla, La Jolla
Moores UCSD Cancer Center, La Jolla
UCSD Medical Center- Hillcrest, San Diego
Bichat-Beaujon Service Inter Hospitalier De Cancerologie, Clichy
University of California Irvine Medical Center, Orange
Alta Bates Summit Comprehensive Cancer Center, Berkeley
The PLA 307 Hospital, Beijing
Zhongshan Hospital Fudan University, Shanghai
Nanjing Bayi Hospital, Nanjing
Jiang Su Cancer Hospital, Nanjing
The First Affiliated Hospital of Anhui Medical University, Hefei
Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Hangzhou
Guangdong General Hospital, Guangzhou
Sasaki Foundation Kyoundo Hospital, Chiyoda-Ku
Gifu Municipal Hospital, Gifu
Hôpital L'Archet Ii, Nice
Prince of Wales Hospital, Shatin, N.T.
Queen Mary Hospital, Hong Kong
Policlinico Universitario Agostino Gemelli, Roma
Unità Operativa Oncologica Medica, Roma
Aichi Cancer Center Central Hospital, Diagnostic and Interventional Radiology, Nagoya
Chiba University Hospital, Chiba
Kanazawa University Hospital, Kanazawa
Kinki University Hospital, Ōsaka-sayama
Shizuoka Cancer Center, Suntou-gun
Nihon University Itabashi Hospital, Itabashi-Ku
Yamanashi Prefectural Central Hospital, Kofu
Fakultna nemocnica s poliklinikou F. D. Roosevelta Banska Bystrica, Banská Bystrica
Narodny onkologicky ustav, Bratislava
POKO Poprad s.r.o., Poprad
Nemocnica Poprad, a.s., Poprad
National Cancer Center/ Center for Liver Cancer, Goyang-si
Samsung Medical Center, Division of Hematology-Oncology, Department of Medicine, Seoul
Asan Medical Center, Division of Oncology, Department of Internal Medicine, Seoul
The Christie NHS Foundation Trust, Withington
Clatterbridge Centre for Oncology NHS Foundation Trust, Liverpool
Royal Liverpool and Broadgreen University Hospital, Liverpool
Royal Free Hospital, London
King's College Hospital NHS Foundation Trust, London
Hammersmith Hospital, London
Lead Sponsor
Pfizer
INDUSTRY